Supplementary Video 1-F2.mp4 (1.71 MB)
Download file

Supplementary Video 1-F2: Cytotoxic T lymphocytes targeting a conserved SARS-CoV-2 spike epitope are efficient serial killers

Download (1.71 MB)
media
posted on 17.03.2022, 13:51 authored by Daniel Meyer, Mohsen Fathi, Lindsey Charley, Laurence Cooper, Navin Varadarajan

Supplementary Video S1: Representative TIMING Videos (each containing one T cell and one or more target cells) displaying killer, non-killer, and serial killer T cells.


Funding

NV was supported by the NIH (R01GM143243), CPRIT (RP180466), MRA Established Investigator Award (509800), NSF (1705464), CDMRP (CA160591), and Owens foundation. DDM, NV, MF, LC and LJNC have equity ownership in CellChorus. LJNC receives royalties from Bristol Myers Squibb (via City of Hope National Medical Center) and Immatics (via MD Anderson Cancer Center), holds receipts of intellectual property rights from Sangamo BioSciences, MD Anderson Cancer Center, and Ziopharm Oncology, and also has equity ownership interest in Targazyme, Ziopharm Oncology, Immatics, Secure Transfusion Services, AuraVax Therapeutics, and IterateBio. NV has equity ownership in AuraVax Therapeutics and owns intellectual property rights from UH.

History